Thus, based on GLP-1 proprieties and physiological effects, longer-acting GLP-1 analogs have been developed to be used as pharmacological tools for type 2 diabetes (T2D) and obesity treatment [9]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.